Pharvaris (NASDAQ:PHVS) Sets New 52-Week High – What’s Next?

Pharvaris N.V. (NASDAQ:PHVS)’s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $35.91 and last traded at $34.58, with a volume of 1030840 shares. The stock had previously closed at $34.71.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Cantor Fitzgerald reaffirmed its Buy rating on Pharvaris, reinforcing a favorable analyst view of the company’s outlook. Cantor Fitzgerald Reaffirms Their Buy Rating on Pharvaris (PHVS)
• Positive Sentiment: PHVS recently set a new 1-year high, showing strong momentum and suggesting investors have been optimistic heading into this period. Pharvaris (NASDAQ:PHVS) Sets New 1-Year High – Still a Buy?
• Neutral Sentiment: Insider trading activity was heavy over June 29-30, with Director Johannes Gerardus Chri Schikan and insider Anne Lesage selling shares at prices around $35.05-$35.49. The sales may create some concern about near-term sentiment, but they do not necessarily indicate a change in the company’s fundamentals. SEC insider filing

Analysts Set New Price Targets

Several brokerages recently issued reports on PHVS. Royal Bank Of Canada cut their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. UBS Group set a $74.00 price objective on shares of Pharvaris in a research note on Wednesday, May 13th. Wolfe Research began coverage on shares of Pharvaris in a research note on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective on the stock. Wedbush raised their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $49.64.

Pharvaris Price Performance

The stock’s 50 day moving average is $31.00 and its two-hundred day moving average is $28.28. The firm has a market capitalization of $2.21 billion, a P/E ratio of -10.65 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.12. As a group, equities research analysts expect that Pharvaris N.V. will post -3.2 EPS for the current year.

Insider Transactions at Pharvaris

In related news, insider Anne Lesage sold 30,703 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,649.47. Following the sale, the insider directly owned 93,969 shares of the company’s stock, valued at approximately $3,334,959.81. The trade was a 24.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the sale, the director directly owned 315,167 shares in the company, valued at $11,185,276.83. This trade represents a 8.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 328,981 shares of company stock valued at $10,458,873. 11.84% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Pharvaris

Institutional investors and hedge funds have recently modified their holdings of the company. General Atlantic L.P. lifted its stake in shares of Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares during the last quarter. Foresite Capital Management IV LLC grew its stake in Pharvaris by 8.3% in the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after buying an additional 368,000 shares during the last quarter. venBio Partners LLC grew its stake in Pharvaris by 8.2% in the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after buying an additional 350,000 shares during the last quarter. Deerfield Management Company L.P. raised its holdings in Pharvaris by 21.1% in the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after acquiring an additional 425,000 shares during the period. Finally, Commodore Capital LP raised its holdings in Pharvaris by 26.5% in the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after acquiring an additional 507,043 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.